Paxmedica reports first patient treated with pax-101 for fatal african sleeping sickness infection

Company provides update on regulatory progress towards us nda submission tarrytown, ny / accesswire / august 27, 2024 / paxmedica, inc. (otc pink:pxmd), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant milestone in its global health efforts. the malawi ministry of health has informed the company that a patient suffering from the potentially fatal parasitic infection known as human africa trypanosomiasis brucei rhodesiense, (hat), commonly referred to as african sleeping sickness, has recently received treatment with pax-101, an intravenous form of suramin, and is recovering at home.
PXMD Ratings Summary
PXMD Quant Ranking